Could GLP-1 Medications Help Treat Asthma in People With Obesity? | Research

The takeaway

GLP-1 receptor agonists may offer a novel treatment approach for obesity-related asthma by addressing the underlying inflammation and metabolic dysfunction that drives this difficult-to-treat phenotype.

Steroid-resistant
obesity-related asthma phenotype may respond to GLP-1 RA therapy instead

What the researchers found

GLP-1 receptor agonists show potential as an innovative treatment for obesity-related asthma through anti-inflammatory, immunomodulatory, and weight-reduction mechanisms.

Why it matters

Obesity-related asthma is notoriously difficult to treat with standard medications; GLP-1 RAs could address the root metabolic causes rather than just symptoms.

The numbers in context

No specific trial data for asthma outcomes; reviews mechanistic evidence and observational signals.

How the study worked

Literature review examining the pathophysiology of obesity-related asthma and the potential therapeutic role of GLP-1 receptor agonists.

Who was studied

Adults with obesity-related asthma

What this study cannot tell us

Review article without original clinical data; dedicated clinical trials of GLP-1 RAs specifically for obesity-related asthma outcomes are still needed.

How to read the evidence

Literature review synthesizing mechanistic and clinical evidence; specific clinical trials for this indication are still emerging.

When this study was published

Published in 2025, reflecting the latest understanding of GLP-1 RAs' anti-inflammatory potential beyond metabolic disease.

The bigger picture

The expanding list of conditions that GLP-1 medications may treat — now including asthma — reflects their broad anti-inflammatory properties beyond simple weight loss and glucose control.

Questions still open

Would GLP-1 RA-mediated weight loss alone explain asthma improvement, or are direct anti-inflammatory effects also at play?
Which specific GLP-1 RA would be most effective for the obesity-asthma phenotype?

Common questions

Why is asthma harder to treat in obese people?

Obesity causes chronic inflammation, immune dysregulation, and metabolic changes that make asthma symptoms worse and reduce the effectiveness of standard treatments like inhaled steroids. This creates a distinct "obesity-related asthma" phenotype.

How might GLP-1 drugs help asthma?

GLP-1 receptor agonists may help through weight reduction, direct anti-inflammatory effects, improved immune regulation, and correction of metabolic dysfunction — addressing the underlying causes of obesity-related asthma rather than just the symptoms.

Read the original research

The Role of GLP-1 Analogues in the Treatment of Obesity-Related Asthma Phenotype.

Biomedicines, 13(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Radzik-Zając, Joanna. (2025). The Role of GLP-1 Analogues in the Treatment of Obesity-Related Asthma Phenotype.. Biomedicines, 13(11). https://doi.org/10.3390/biomedicines13112610